企業プロフィール
Cerevel 株価・ニュース・カタリスト
- ティッカー:
- CERE
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- United States
株価変動の要因
Current closing-price context is not available for CERE.
企業概要
事業概要
Cerevel Therapeutics was a neuroscience biotech focused on receptor pharmacology and CNS drug development before being acquired by AbbVie.
所在地とセクター分類
Headquartered in the United States and listed on NASDAQ prior to acquisition, it sat in CNS biotechnology.
ビジネスモデルの特徴
The story was built around clinical-stage psychiatry and neurology programs, with valuation tied to pipeline data and strategic interest.
バイオ業界での位置付け
Cerevel was a high-quality neuroscience catalyst name and now belongs to biotech M&A history.
今後のカタリスト
- Cerevel’s near-term catalyst is mostly transaction resolution and any final closeout / integration-related milestone tied to the company’s acquired pipeline assets. The next update will help show whether the company is moving from promise to a more de-risked stage of execution. Investors will care less about the label than about whether the platform can keep producing credible next steps.
最近のニュース
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。